CN107034217A - Promoter, recombinant mesenchymal stem cell, and preparation method and application thereof - Google Patents
Promoter, recombinant mesenchymal stem cell, and preparation method and application thereof Download PDFInfo
- Publication number
- CN107034217A CN107034217A CN201611200969.9A CN201611200969A CN107034217A CN 107034217 A CN107034217 A CN 107034217A CN 201611200969 A CN201611200969 A CN 201611200969A CN 107034217 A CN107034217 A CN 107034217A
- Authority
- CN
- China
- Prior art keywords
- tnf
- stem cell
- plasmid
- promoter
- alpha antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 210000002901 mesenchymal stem cell Anatomy 0.000 title abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 75
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000013612 plasmid Substances 0.000 claims description 68
- 210000000130 stem cell Anatomy 0.000 claims description 63
- 210000004027 cell Anatomy 0.000 claims description 61
- 241000700605 Viruses Species 0.000 claims description 54
- 239000013613 expression plasmid Substances 0.000 claims description 28
- 239000013600 plasmid vector Substances 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 230000029087 digestion Effects 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 16
- 239000011259 mixed solution Substances 0.000 claims description 14
- 238000004806 packaging method and process Methods 0.000 claims description 14
- 102000012410 DNA Ligases Human genes 0.000 claims description 13
- 108010061982 DNA Ligases Proteins 0.000 claims description 13
- 239000007853 buffer solution Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- 108010042407 Endonucleases Proteins 0.000 claims description 10
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 235000015097 nutrients Nutrition 0.000 claims description 8
- 230000035939 shock Effects 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 5
- 102000004533 Endonucleases Human genes 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 13
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000004957 immunoregulator effect Effects 0.000 abstract 1
- 239000005090 green fluorescent protein Substances 0.000 description 44
- 230000014509 gene expression Effects 0.000 description 31
- 206010061218 Inflammation Diseases 0.000 description 24
- 230000004054 inflammatory process Effects 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000001514 detection method Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 10
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 102100031780 Endonuclease Human genes 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 9
- 238000001764 infiltration Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 102100030703 Interleukin-22 Human genes 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 210000004969 inflammatory cell Anatomy 0.000 description 7
- 108010074109 interleukin-22 Proteins 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000001258 synovial membrane Anatomy 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 206010041047 Slow virus infection Diseases 0.000 description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000007365 immunoregulation Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 229950006790 adenosine phosphate Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 101000756628 Mus musculus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000009124 positive feedback regulation Effects 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a promoter, a recombinant mesenchymal stem cell, and a preparation method and application thereof. The promoter has the sequence shown in SEQ ID NO. 2, and can positively activate and express TNF alpha antibody gene in the presence of inflammatory factor TNF alpha. A preparation method of the recombinant mesenchymal stem cells utilizes the promoter to prepare the recombinant mesenchymal stem cells. The invention also provides the recombinant mesenchymal stem cell prepared by the preparation method of the recombinant mesenchymal stem cell, and the recombinant mesenchymal stem cell can be activated by an inflammatory factor TNF alpha under an inflammatory environment and can be stably combined with an inflammatory site, so that the anti-inflammatory and immunoregulatory capacity of the mesenchymal stem cell is enhanced, and the recombinant mesenchymal stem cell can be used for treating osteoarthritis and has a good treatment effect. The invention also provides application of the recombinant mesenchymal stem cells, the recombinant mesenchymal stem cells are used for preparing a medicament for treating osteoarthritis, and the obtained medicament has a good effect of treating osteoarthritis.
Description
【Technical field】
The present invention relates to biomedicine technical field, and in particular to a kind of promoter, restructuring interstital stem cell and its preparation
Methods and applications.
【Background technology】
Osteoarthritis (OA, osteoarthritis) also known as degenerative osteoarthritis, are the retrogression of articular cartilage, and
There is spur to be formed in joint margins.With the extension of average human life, the incidence of disease more and more higher of osteoarthritis.Inflammation can be led
The regression of cartilage is caused, and cartilage degeneration can stimulate the deterioration of inflammation, so that the state of an illness is further serious.
Treatment osteoarthritis method mainly have physical treatment and drug therapy, physical treatment mainly for patients with mild,
Reach the purpose for mitigating pain and maintaining function of joint.The medicine that drug therapy is used mainly has:Antalgesic, cox 2 inhibitor,
Steroids, synovia replenishers etc..However, the limited efficacy of these treatment methods, specificity is not obvious, it is impossible to be effectively improved disease
Feelings.
【The content of the invention】
To overcome the technical problem that existing osteoarthritis treatment method effect is poor, the present invention provides a kind of promoter, again
Group interstital stem cell and its preparation method and application.
The present invention is to provide a kind of promoter, the sequence of the promoter to solve a technical scheme of above-mentioned technical problem
Such as SEQ ID NO:Shown in 2.
The present invention also provides a kind of preparation method for recombinating interstital stem cell, including:There is provided TNF Alpha antibodies gene and above-mentioned
Promoter, structure obtain slow virus expression plasmid;Wherein, the sequence of the TNF Alpha antibodies gene such as SEQ ID NO:1 institute
Show;The slow virus expression plasmid is subjected to slow virus packaging, virus liquid is obtained;Mesenchyma is infected in the virus liquid dry thin
Born of the same parents, obtain required restructuring interstital stem cell.
Preferably, the structure of the slow virus expression plasmid includes:Step S11:By the TNF Alpha antibodies gene and described
Promoter is cloned into shuttle plasmid pGFP, obtains shuttle plasmid TNF α-GFP;Step S12:With the shuttle plasmid TNF α-
GFP adds the TNF Alpha antibodies gene and obtains TNF α-AB plasmid vectors as carrier;Step S13:Convert the TNF α-
AB plasmid vectors simultaneously carry out plasmid extraction and obtain the slow virus expression plasmid.
Preferably, the TNF Alpha antibodies gene by using endonuclease Xho1 and endonuclease Xba1 to described
Shuttle plasmid TNF α-GFP carry out double digestion and obtained.
Preferably, the time of the double digestion is 3-24h.
Preferably, the step S12 is to be attached instead using TNF Alpha antibodies gene and shuttle plasmid TNF α-GFP
Should, obtain TNF α-AB plasmid vectors;The concentration of shuttle plasmid TNF α-GFP described in the reaction system of the coupled reaction is
2-3ng/ μ L, the TNF Alpha antibodies gene molal quantity is 2-4 times of the shuttle plasmid TNF α-GFP molal quantitys.
Preferably, the step S12, which is additionally included in reaction system, adds DNA ligase and connection buffer solution;It is described anti-
The percent by volume for answering DNA ligase in system is 2-3%, and the percent by volume of connection buffer solution is 8-12%.
Preferably, the TNF α-AB plasmid vectors are converted and specifically includes following steps:TNF α-AB the plasmids are carried
Body is added in bacillus coli DH 5 alpha competent cell, and mixed solution is obtained after being well mixed;By mixed solution ice bath 20-
50min, ice bath 1-4min again after acting on 30-90s through 40-45 DEG C of heat shock;Then mixed solution is placed in culture medium and cultivated,
Obtain the nutrient solution containing the slow virus expression plasmid.
The present invention also provides a kind of restructuring interstital stem cell, and the restructuring interstital stem cell is integrated with promoter and TNF α are anti-
Body gene;The sequence of the promoter such as SEQ ID NO:Shown in 2, the sequence such as SEQ ID NO of the TNF Alpha antibodies gene:1
It is shown.
The present invention also provides a kind of application for recombinating interstital stem cell, and above-mentioned restructuring interstital stem cell is used to prepare and treated
The medicine of osteoarthritis.
Relative to prior art, a kind of promoter provided by the present invention, the promoter can be deposited in inflammatory factor TNF α
Positive activation expression TNF Alpha antibodies genes, can obtain being used to treat osteoarthritis and treatment using the promoter in case
The good restructuring interstital stem cell of effect.
A kind of preparation method for restructuring interstital stem cell that the present invention is also provided, restructuring is prepared using above-mentioned promoter
Interstital stem cell, the restructuring interstital stem cell can be activated under inflammatory environment by inflammatory factor TNF α, can be stably coupled to inflammation
Disease site, so as to strengthen the anti-inflammatory and immunoregulation capability of mescenchymal stem cell, thus can be used to treat osteoarthritis and treatment
Effect is good.
The present invention also provides in a kind of restructuring interstital stem cell, the restructuring interstital stem cell and is integrated with promoter and TNF α
Antibody gene, can be activated by inflammatory factor TNF α under inflammatory environment, inflammation sites can be stably coupled to, so that between strengthening
The anti-inflammatory and immunoregulation capability of mesenchymal stem cells, thus can be used to treat osteoarthritis and therapeutic effect is good.
The present invention also provides a kind of application for recombinating interstital stem cell, and above-mentioned restructuring interstital stem cell is used to prepare and treated
The medicine of osteoarthritis, the effect of resulting drug therapy osteoarthritis is good.
【Brief description of the drawings】
Fig. 1 is the schematic flow sheet of the preparation method of restructuring interstital stem cell in the present invention.
Fig. 2 is the step S1 of the preparation method of restructuring interstital stem cell in present invention schematic flow sheet.
Fig. 3 is the collection of illustrative plates of shuttle plasmid pGFP in the present invention.
Fig. 4 is the collection of illustrative plates of shuttle plasmid TNF α-GFP in the present invention.
Fig. 5 is the collection of illustrative plates of third generation slow virus packaging plasmid in the present invention.
Fig. 6 is the structural representation of the promoter of addition translation sequences and green fluorescent protein sequence in the present invention.
Fig. 7 is the efficiency qualification figure after slow-virus infection MSC in the present invention.
Fig. 8 is that RT-PCR detects MSC after slow-virus infection in the present invention, TNF α-AB expression.
Fig. 9 is the expression of TNF α-AB in western blotting detection cells.
Figure 10 is whether HE dyeing detections tissue inflammation Infiltrating after treatment improves.
Figure 11 detects for the propagation of elisa technique inflammation Mouse spleen cells after treatment.
Figure 12 is the expression that elisa technique detects the inflammation mouse inflammatory factor after treatment.
Figure 13 is the expression that Real-time round pcrs detect the inflammatory factor in inflammation mouse mRNA level in-site after treatment.
【Embodiment】
In order that the purpose of the present invention, technical scheme and advantage are more clearly understood, below in conjunction with accompanying drawing and embodiment,
The present invention will be described in further detail.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention,
It is not intended to limit the present invention.
Embodiment one
The present invention provides a kind of promoter, the sequence such as SEQ ID NO of the promoter:Shown in 2.The promoter can be
Positive activation expression TNF Alpha antibodies genes in the presence of inflammatory factor TNF α, can obtain being used to treat using the promoter
Osteoarthritis and the good restructuring interstital stem cell of therapeutic effect.
Promoter provided by the present invention positive activation expression TNF Alpha antibodies in the presence of inflammatory factor TNF α
The mechanism of action of gene is:Inflammatory factor TNF α have multiple downstream signaling pathways, one downstream signaling pathway of most important of which
It is the activation of NF- κ B transcription factors;And inflammatory factor TNF α activation NF- κ B paths have numerous signaling molecules to participate in, such as TNFR phases
Close the factor, receptor interacting protein (RIP, Receptor-interacting protein), MAPK 3
(MAP3K, mitogen-activated protein kinase ki-nase 3), IKK compounds, IL-10 (IL-10)
Deng;The present invention IL-10 in close relations with inflammatory factor TNF α is filtered out in numerous signaling molecules, by by IL-10 with
CAG promoters are combined to obtain the promoter.Therefore when inflammatory factor TNF alpha expressions are raised, it can activate IL-10's
Expression, the promoter designed accordingly can positive activation expression TNF Alpha antibodies genes.
Embodiment two
As shown in figure 1, a kind of preparation method for recombinating interstital stem cell, including:
Step S1:TNF Alpha antibodies gene and above-mentioned promoter are provided, structure obtains slow virus expression plasmid;Wherein, institute
State the sequence such as SEQ ID NO of TNF Alpha antibodies genes:Shown in 1;
Step S2:The slow virus expression plasmid is subjected to slow virus packaging, virus liquid is obtained;
Step S3:Mescenchymal stem cell is infected in the virus liquid, required restructuring interstital stem cell is obtained.Wherein,
Mescenchymal stem cell (MSC) can directly be bought, or be extracted from marrow.In the concrete operations of the present invention
It is to extract to obtain MSC from C57/BL6 mouse bone marrow cells, C57/BL6 mouse are purchased from Hong Kong University's Experimental Animal Center.
Restructuring interstital stem cell is prepared using above-mentioned promoter, the restructuring interstital stem cell can quilt under inflammatory environment
Inflammatory factor TNF α are activated, and inflammation sites can be stably coupled to, so as to strengthen anti-inflammatory and the immunological regulation of mescenchymal stem cell
Ability, thus can be used to treat osteoarthritis and therapeutic effect is good.
It is preferred that, also referring to Fig. 2, the structure of step S1 namely the slow virus expression plasmid includes:
Step S11:The TNF Alpha antibodies gene and the promoter are cloned into shuttle plasmid pGFP, shuttle matter is obtained
Grain TNF α-GFP;
Step S12:Using the shuttle plasmid TNF α-GFP as carrier, add the TNF Alpha antibodies gene and obtain TNF
α-AB plasmid vectors;
Step S13:Convert the TNF α-AB plasmid vectors and carry out plasmid extraction and obtain the slow virus expression plasmid.
By the way that TNF Alpha antibodies gene and promoter are cloned into shuttle plasmid pGFP, and with the shuttle plasmid TNF of acquisition
α-GFP are carrier, TNF Alpha antibodies genes are added, so that the TNF containing TNF Alpha antibodies gene and promoter stablized
α-AB plasmid vectors;And the promoter can be allowed to work and expression TNF Alpha antibodies genes;Inverted TNF α-AB plasmid vectors
And carry out the slow virus expression plasmid needed for plasmid extraction is obtained.
Wherein shuttle plasmid pGFP is provided by Guangzhou FulenGen Co., Ltd., and the collection of illustrative plates of the shuttle plasmid pGFP is as schemed
Shown in 3.Shuttle plasmid TNF α-GFP collection of illustrative plates is as shown in figure 4, the IL-CAG promoter in Fig. 4 are the promoter.
Preferably, the TNF Alpha antibodies gene by using endonuclease Xho1 and endonuclease Xba1 to described
Shuttle plasmid TNF α-GFP carry out double digestion and obtained.TNF Alpha antibodies genes are obtained using the shuttle plasmid TNF α-GFP, are protected
The uniformity of TNF Alpha antibodies genes used in whole preparation process is demonstrate,proved, so as to ensure that the restructuring interstitial of final gained is dry thin
The stability of born of the same parents.And according to shuttle plasmid TNF α-GFP gene order, restriction endonuclease is selected, i.e., from core
Sour restriction endonuclease Xho1 and endonuclease Xba1 carry out double digestion, so as to ensure to obtain complete and stable TNF Alpha antibodies genes.
Certainly in other embodiment, due to having been given by the sequence of TNF Alpha antibodies genes, directly it can also synthesize or utilize
PCR amplification techniques obtain the TNF Alpha antibodies gene.
Preferably, the time of the double digestion is 3-24h.It so can guarantee that the effect of digestion, i.e. digestion are complete.Wherein more
It is 6-12h the times of double digestion that good, which is,.
Preferably, the step S12 is to be attached instead using TNF Alpha antibodies gene and shuttle plasmid TNF α-GFP
Should, obtain TNF α-AB plasmid vectors;The concentration of shuttle plasmid TNF α-GFP described in the reaction system of the coupled reaction is
2-3ng/ μ L, the TNF Alpha antibodies gene molal quantity is 2-4 times of the shuttle plasmid TNF α-GFP molal quantitys.
By determining shuttle plasmid TNF α-GFP concentration and TNF Alpha antibodies gene with shuttle plasmid TNF α-GFP's
Amount ratio between molal quantity, the coupled reaction is relatively stable, and can effectively reduce the impurity in reaction product, miscellaneous herein
Matter refers to the material in addition to required TNF α-AB plasmid vectors.It is preferred that the shuttle plasmid TNF α-GFP's is dense
Spend for 2.5ng/ μ L, the TNF Alpha antibodies gene molal quantity is 3 times of the shuttle plasmid TNF α-GFP molal quantitys.
Preferably, the step S12, which is additionally included in reaction system, adds DNA ligase and connection buffer solution;It is described anti-
The percent by volume for answering DNA ligase in system is 2-3%, and the percent by volume of connection buffer solution is 8-12%.By determining
DNA ligase and the percent by volume for connecting buffer solution, it is ensured that the rapidity and stability of reaction.Wherein, DNA ligase is T4
DNA ligase, connection buffer solution is 10 × Ligation Buffer;In preferably embodiment, DNA in the reaction system
The percent by volume of ligase is 2.5%, and the percent by volume of connection buffer solution is 10%.
Specifically, so that the reaction system cumulative volume of coupled reaction is 20 μ L as an example, including 50ng in reaction system and shuttling
Plasmid TNF α-GFP, 2 μ 10 × Ligation of L Buffer, 0.5 μ L T4 DNA ligase, then add distilled water or ultrapure
Water is to 20 μ L.
Preferably, TNF α-AB plasmid vectors in the step S13 are converted and specifically include following steps:By the TNF α-
AB plasmid vectors are added in bacillus coli DH 5 alpha competent cell, and mixed solution is obtained after being well mixed;By the mixed solution ice
20-50min is bathed, ice bath cools down 1-4min again after acting on 30-90s through 40-45 DEG C of heat shock;Then mixed solution is placed in culture
Cultivated in base, obtain the nutrient solution containing the slow virus expression plasmid.First, by thin from bacillus coli DH 5 alpha competence
Born of the same parents, both can guarantee that the expression of TNF α-AB plasmid vectors, and will not cause negative shadow to the conversion of TNF α-AB plasmid vectors
Ring, the negative effect at this refers to that the TNF α-AB plasmid vectors that can degrade are not present in bacillus coli DH 5 alpha competent cell
Special inscribe enzyme system, and the DNA of TNF α-AB plasmid vectors is not modified etc..Secondly, by by mixed solution
Heat shock after ice bath 20-50min, is and then placed in the operation of 1-4min on ice, it is ensured that transformation efficiency.
Specifically, it is thin the reaction product obtained after coupled reaction directly can be directly added into bacillus coli DH 5 alpha competence
In born of the same parents.Such as, reaction product described in taking 12 μ L is added in 50 μ L bacillus coli DH 5 alpha competent cells, is gently mixed, ice bath
30min;Carry out heat shock again, 42 DEG C of metal bath 50s, ice bath 1-2min again, adds 500 μ L and has been incubated to 37 DEG C of nonreactives rapidly
The LB culture mediums of property;At 37 DEG C, shaking table culture 1h under conditions of 200rpm is centrifuged with 8000rpm rotating speed after culture, goes to part
It is coated on after supernatant on the LB flat boards containing adenylic acid (AMP, adenosine monophosphate), training is inverted at 37 DEG C
Support overnight;Picking monoclonal bacterium colony is in the LB culture mediums of non-resistant, and by volume 1:300 add AMP, in 37 DEG C, 200rpm
Under conditions of shaking table culture 12h, obtain nutrient solution.
Plasmid extraction is carried out after conversion obtains the nutrient solution can obtain the slow virus expression plasmid.Plasmid extraction
It is to remove the impurity such as RNA, protein, obtain relatively pure slow virus expression plasmid.Specifically, can use plasmid
Small extraction reagent kit Lot# L0802 carry out plasmid extraction, and step is as follows:
1) column equilibration, adsorption column adds 500 μ L equilibrium liquids, 12000rpm centrifugations 1min;
2) nutrient solution 3mL overnight is taken, is added in two times in 1.5mLEP pipes, 12000rpm centrifugation 1min are suctioned out as far as possible
Clear liquid, collects somatic cells;
3) 250 μ L solution P1 are added into precipitation, thoroughly suspended precipitation with rifle;
4) 250 μ L solution P2 are added, gently spins upside down 6~8 times, thalline is fully dissolved;
5) 350 μ L solution P3 are added, are gently spun upside down immediately 6~8 times until there is flocculent deposit, 12000rpm is centrifuged
10min;
6) supernatant is added in adsorption column, 12000rpm centrifugation 30s repeat step operation once;
7) 600 μ L rinsing liquid is added, 12000rpm centrifugation 30s repeat step operation once;
8) 12000rpm centrifuges 2min, removes rinsing liquid, room temperature, which is uncapped, dries;
9) 40 μ L ddH2O elutions are added, are stood in 2min, 12000rpm centrifugation 2min obtain slow virus expression plasmid
TNF α-GFP。
Wherein, equilibrium liquid used, solution P1, solution P2, solution P3 and rinsing liquid are the small extraction reagent kit Lot# of plasmid
There is provided in L0802.
Be further, in step s 2, slow virus packaging be by the slow virus expression plasmid and package carrier together
Transfection of packaging cells, you can obtain required virus liquid.It can be specifically to select 239FT cells as incasing cells, and make
Slow virus is carried out with the kits of Lipofectamine 2000 to pack.Preferably, before slow virus packaging, namely transfection is carried out
24h, digests 293FT cells and counts, with 5 × 106It is inoculated in 10cm culture dishes, 293FT cell confluencies when transfecting it
Up to 80%~90%.
The step of can then proceed in 2000 specifications of Lipofectamine, by slow virus expression plasmid TNF α-GFP
And shuttle plasmid pGFP is separately added into after slow virus packaging plasmid, Transfection of packaging cells 293FT.Plasmid consumption is respectively (10 μ g
PGFP+6.52 μ g pMDL+2.52 μ g pRSV-REV+3.52 μ g pMD2.G) and (36 μ g TNF α-GFP+12 μ g pMDL+6 μ
g pRSV-REV+18μg pMD2.G).Transfect after 48h, the viral supernatants that harvest incasing cells 293FT is produced are placed in 4 DEG C of temperature
It is lower temporary.Fresh 293FT culture mediums are added, 24h is further cultured for, on second of collection viral supernatants, with the virus of first time collection
Clear mixing, through 0.45 μm of membrane filtration and according to Peg-it specifications by viral concentration.Virus liquid after packing concentration, be placed in-
Preserved at a temperature of 80 DEG C.
Wherein, the third generation slow virus packaging plasmid that slow virus packaging plasmid provides for addgene companies, the third generation is slow
The collection of illustrative plates of viral packaging plasmid is as shown in Figure 5.
As it was noted above, mescenchymal stem cell (MSC) can be extracted from marrow.MSC extraction can be with
It is to be obtained by bone marrow irrigation method:Heteroproteose cell is gone by stationary culture, about pass on 4 times after, under microscope visible MSC be compared with
The spindle shape of rule, arranges directional, swirling, radial growth tendency is presented.
The infection of mescenchymal stem cell is specifically as follows in step s3:Digestion MSC cells are simultaneously counted, with 1 × 106Per hole
Density be inoculated in 6 orifice plates, viral supernatants and Polybrene (final concentration of 8 μ g/mL) are added in 6 orifice plates.
Embodiment three
One kind restructuring interstital stem cell, is integrated with promoter and TNF Alpha antibodies genes;The sequence of the promoter such as SEQ
ID NO:Shown in 2, the sequence such as SEQ ID NO of the TNF Alpha antibodies gene:Shown in 1.Use above-mentioned restructuring interstital stem cell
Preparation method prepare.Promoter and TNF Alpha antibodies genes are integrated with the restructuring interstital stem cell, under inflammatory environment
It can be activated by inflammatory factor TNF α, inflammation sites can be stably coupled to, so as to strengthen the anti-inflammatory of mescenchymal stem cell with being immunized
Regulating power, thus can be used to treat osteoarthritis and therapeutic effect is good.
Example IV
A kind of application for recombinating interstital stem cell, above-mentioned restructuring interstital stem cell is used for the medicine for preparing treatment osteoarthritis
Thing, the effect of resulting drug therapy osteoarthritis is good.The restructuring interstital stem cell can be administered alone, or with medicine
The form administration of composition.It is appreciated that described pharmaceutical composition includes restructuring interstital stem cell and carrier or excipient.It is made
Dosage form formula depends on selected method of administration, can be manufactured according to general knowledge well known in the art, and the restructuring interstitial is done
Cell is present in the medium of cytocompatibility, in such as 0.9% physiological saline or is made slow controlling agent.
An experimental group, an empty vector control group and a blank control group is set to be tested.Experimental group is with this
The MSC infected in invention using the slow virus expression plasmid, that is, the restructuring interstitial obtained after being recombinated are dry carefully
Born of the same parents, are designated as MSC-TNF α-AB.Empty vector control group is the MSC using shuttle plasmid pGFP infection, is designated as MSCe.Blank control
Group is the MSC for not carrying out slow-virus infection, is designated as MSC.
And be identified through successfully infecting in virus liquid made from the slow virus expression plasmid for convenience it is described between fill
Matter stem cell, can be that one section of translation sequences and fluorescent protein sequence are designed in the promoter.As shown in fig. 6, described
Translation sequences (IRES) and green fluorescent protein sequence (GFP, Green Fluorescent Protein) are added in promoter.
Cell so after mescenchymal stem cell infects successfully, by microscope it is observed that cell sends green fluorescence.Specifically
, the expression of green fluorescent protein (GFP) is observed under fluorescence inverted microscope after infection 48h.I.e. in 488nm wavelength
Under exciting light, it is seen that most cells send green fluorescence.
First, the efficiency identification after slow-virus infection
To above-mentioned experimental group, empty vector control group and blank control group carry out infection test, as a result as shown in fig. 7,
Occurs green fluorescent protein (GFP) expression in MSC-TNF α-AB and MSCe, the expression without GFP in MSC.
2nd, the expression identification of TNF Alpha antibodies gene (TNF α-AB)
The table of TNF Alpha antibodies gene (TNF α-AB) is carried out to above-mentioned experimental group, empty vector control group and blank control group
Up to identification.Concrete operations are:
1 × 10 is collected respectively6MSC, MSCe and MSC-TNF α-AB, according to the RNeasy Mini of QIAGEN companies
Kit (catalog number (Cat.No.) 74104) extracts cell total rna, according to the Prime Script First StOAndcDNA of TakaOA companies
Synthesis Kit (catalog number (Cat.No.) 6110A) Reverse Transcriptase kit specification, is cDNA by total serum IgE reverse transcription, uses TaKaOATaqTM
(catalog number (Cat.No.) R001A) and it is that annealing temperature enters performing PCR with 60 DEG C.
PCR the primer sequences are as follows:
Mouse MSC-TNF α-AB gene outcomes length (257bp):
F:5’-GCTAGAGTGGCTCTCGCA-3’(SEQ ID NO:3)
R:5’-CGAAGGGGCGGAACTTAA-3’(SEQ ID NO:4)
Mouse β-actin gene (Genbank accession numbers:NM_007393.3) (product length 448bp):
F:5’-AGAGGGAAATCGTGCGTGAC-3’(SEQ ID NO:5)
R:5’-TGCTGGAAGGTGGACAGTGAG-3’(SEQ ID NO:6)
As a result show, compared to blank control group MSC and empty vector control group MSCe, experimental group MSC-TNF α-AB viruses
TNF α-AB expressions are significantly improved (Fig. 8) in metainfective MSC-TNF α-AB cells, it was demonstrated that and experimental group MSC-TNF α-
AB virus infection MSC works well, and can stabilize it overexpression TNF α-AB.
3rd, the MSC-TNF α-AB that detection is built can be started by inflammatory factor TNF α specific regulatings
To detect the expression of the TNF α-AB after inflammatory factor TNF α are added in external MSC cell culture.
1.MSC-TNF α-AB cell culture:
MSC-TNF α-AB cell culture mediums are:Contain 10% hyclone (FBS) in DMEF/F12 culture mediums,
100U/mL mycillins, 1% nonessential amino acid, 0.1% beta -mercaptoethanol, 5ng/mL EGF, 5ng/mL FGF.
1) before sterile culture is carried out, by laboratory material requested autoclaving;Ultra violet lamp 30min;Dress cell
Between Special experimental clothes and gloves, with 75% alcohol wipe both hands;Under microscope, cell state is observed, cell density is converged to
More than 70% then needs passage, closes uviol lamp, opens blower fan, while wiping super-clean bench with cotton ball soaked in alcohol, lights alcolhol burner.
2) culture dish lid is being opened, is removing cells and supernatant, after PBS washings, remove PBS.
3) pancreatin is added in culture dish, 13min is placed in incubator.Observed at any time under microscope, see the prominent of cell
Rise and disappear, become bowlder, isometric complete medium is added immediately and terminates digestion.It is careful not to digestion time long, otherwise cell
It can be digested by pancreatin.
4) pipettor is gently blown and beaten after terminating, and makes it from being come off in bottle wall and being distributed to culture medium, draws cell suspension simultaneously
It is transferred in EP pipes, 400xg centrifugations 3min.Be resuspended cell, and according to experiment purpose and cell habit by different proportion point ware after
Continuous culture.
5) observed after passing on, pass on or change 24~48h of liquid, notice whether cell is contaminated, the cell culture fluid of pollution becomes
It is visible under muddiness, mirror to have a large amount of mycelia or other suspended things.If cell growth is slow, growth characteristics change, kytoplasm endoparticle
Property material increases, although nutrient solution does not become cloudy, it is considered to may have mycoplasma contamination.
2.Western Blot detect that MSC-TNF α-AB activate situation by inflammatory factor TNF α
The TNF α inflammatory factors for choosing 50 μm of oL/L concentration handle the MSC-TNF α-AB cells of logarithmic phase, are placed in light microscopic
Lower observation, cell in-vitro growth is good, and cell is in fusiformis, and profile understands.In order to determine TNF α-AB expression, it have chosen
MSC groups (control group), TNF α-group (not plus inflammatory factor TNF α stimulate) and TNF α+group are (plus inflammatory factor TNF α are pierced
Swash) while having carried out total protein extraction.The protein extraction uses RIPA (Sigma, catalog number (Cat.No.) R0278) reagent, according to explanation
Book is carried out.
Adjustment cell density is 70%-80%, and PBS washes cell twice, adds 8mL without phenol red DMEM (GIB CO, catalog number (Cat.No.)
21063-029).Albumen is collected after cell is cracked, gained cell protein passes through (BOAdford (BIO-OAD), catalog number (Cat.No.)
5000202) method is carried out after quantifying, for the experiment of conventional western blotting (immunoblotting).Detect target protein
For TNF α-AB, internal reference is β-actin (Santa Cruz, catalog number (Cat.No.) SC-47778), and Western Blot results show TNF
α+group TNF α-AB expression is substantially (Fig. 9).
TNF α are one of important inflammatory factors, add TNF α inflammatory factors processing MSC-TNF α-AB cells and meet inflammation
The actual conditions of disease infiltration.Experiment shows that the novel cell lines transformed by the present invention are stimulated without TNF α inflammatory factors
When, TNF α-AB will not be expressed.And under the stimulation of TNF α inflammatory factors, play its positive feedback regulation up-regulation TNF α-AB's
Clearly, the cell line MSC-TNF α-AB of this explanation present invention reach expected experiment purpose for expression.
4th, HE dyeing identification inflammatory tissue
Mouse osteoarthritis is classical transplantation model, and the present embodiment applies the transplantation model.
1. prepare osteoarthritis inflammatory infiltration mouse model
The solution that concentration is 1mg/mL, the freund adjuvant with equivalent is made in the acetic acid that the natural collagen of purifying is dissolved in 11M
Or Freund's incomplete adjuvant is mixed into stable emulsion;Intracutaneous, the injection site meeting with 1mL 4~6 injection location mouse backs of emulsion point
There is aphtha (self-healing after 7~10 days);After 21 days, in the acetic acid that 15mg collagens are dissolved in 15mL 1M, mouse peritoneal is injected
It is immunized again.
After initial injection after 14~60 days, there is redness and swelling of joints, typically occur in joint distal end, metapedes ankle-joint is most normal
The position of accumulation.Acute stage pathological change can be divided into for two phases, after being immunized 10 days, intra-articular only some fibre deposit and synovial membrane
Cell is without change;After 12 days, the visible ankle-joint of naked eyes is red and swollen, and red and swollen, light microscopic inferior synovial membrane cytosis, stratum synoviale occurs in knee joint
Number increases to 3~7 layers, and is creeped to cartilage bone face, and synovial membrane and synovial membrane the following group are woven with fiber deposition.Then see that synovial cell becomes under Electronic Speculum
Circle, cell contact is reduced, and filopodia increases, and intracellular lysosome and endoplasmic reticulum increase, increased;Enter second after 19 days
Phase, the synovial membrane of hyperplasia is thickened by 6~10 μm to 200~250 μm, pannus is formed, wherein having a large amount of monocytes, polymorphonuclear huge
Cell, macrophage, form microabscess around capilary, it is seen that the soft tissue of monocyte intrusion cartilage junction;6~
After 7 weeks, inflammation enters chronic phase, and oedema is still suffered from, and the cell of infiltration is intra-articular scar occur based on CD+4 T cell,
Granular hyperplastic tissue, cartilage and subchondral bone are destroyed, and are finally resulted in osteoarthritis and are formed.
2. transplanting detection
Respectively by 2 × 106MSC-TNF α-AB, MSC, and isometric PBS (Control groups) is transplanted to affected part.One
Zhou Yihou puts to death mouse anesthesia, cervical dislocation, gathers mouse tissue, and 4% paraformaldehyde carries out routine paraffin wax embedding after fixing
With HE dyeing, the preservation situation of transplantation site cell and the Infiltrating of immunocyte are observed.HE staining analysis shows,
Control group inflammatory cell infiltrations are obvious.MSC-TNF α-AB groups significantly reduce the infiltration of inflammatory cell, and MSCs groups inflammation is delayed
Solution situation randomly selects three sections of every Recipient mice and counts (400 times) under high power field between two groups, system
Count the inflammatory cell number of Recipient mice.
As a result show, the average inflammation cell number of PBS groups infiltration organizes the flat of infiltration for 235 ± 70.4, MSC-TNF α-AB
Equal inflammatory cell number is that the average inflammation cell number of 103.4 ± 29.6, MSCs groups infiltration is 112.8 ± 15.2.The as shown by data,
MSC-TNF α-AB transplantation groups more obviously reduce inflammatory reaction, alleviate inflammatory symptom, have reached the expected treatment of the present invention
Effect (Figure 10).
5th, inflammatory factor change detection
The present invention acquires Recipient mice spleen, and separating mouse spleen cell has carried out Spleen cell proliferation detection, and CD4+T is thin
Born of the same parents, CD3+T cells, the analysis detection of TH1 and TH2 cell subsets, and conventional inflammation in inflammatory factor mRNA level in-site and serum
The detection of factor protein level.
By mouse boosting cell in vitro culture 72h, before 12h is reached, 1 × BrdU is added.And carry out BrdU and MTT detections.
As a result as shown in figure 11, in the optical density (OD values) that (A) obtains for the 450nm wavelength of progress BrdU detections in Figure 11, Figure 11 (B)
To carry out the optical density (OD values) that the 570nm wavelength of MTT detections is obtained.As a result show:In terms of cell propagation, Control groups
Substantially, MSC-TNF α-AB groups have relatively low propagation level to proliferation of inflammatory cells, and MSC groups are between the two.This shows
MSCs-TNF AB can effectively suppress the proliferative conditions (Figure 11) of inflammatory cell.
The subgroup change of present invention analysis detection splenocyte kind T cell.Detection find, MSC-TNF α-AB group treatment by
Body mouse boosting cell kind Th cells and Th2 and entirety CD4+T cell subsets ratios are substantially reduced, and are as a result represented, MSC-TNF
α-AB treatments substantially inhibit T cell number in Mice Body, reduce Th1 cells and Th2 cell subsets ratios
In order to further determine that the expression of inflammatory cell, dropped present invention detects whether the ratio of overall T cell
Low, CD3 is the surface marker of T cell, the present invention have detected treated mouse boosting cell CD3+ T cell ratio and
FOXp3 regulatory T cells (Treg).As a result show, MSC-TNF α-AB group CD3T cell proportions are substantially reduced, by 23.1%
Drop to 17.4%, Treg ratios substantially to rise, 4.32% is risen to by 2.9%.Result above shows, MSC-TNF α-AB energy
It is enough effectively to suppress T cell ratio, promote regulatory T cells increase.In addition the present invention passes through Real-timePCR and elisa technique
Conventional inflammatory factor interleukin-22 (IL-2), IL-4 (IL-4), IL-10, interferon in spleen and serum are have detected respectively
(IFN-γ), transforming growth factor-β (TGF-β) and Foxp3 expression;That is (A) is to be detected using elisa technique in Figure 12
(B) is to detect that (C) is to utilize ELISA in obtained IL-4 concentration, Figure 12 using elisa technique in the IL-2 concentration arrived, Figure 12
(D) is that obtained IFN-γ concentration, Tu12Zhong are detected using elisa technique in the IL-10 concentration that technology for detection is obtained, Figure 12
(E) it is that obtained Foxp3 concentration is detected using elisa technique.ELISA experiments use kit (USCN, catalog number (Cat.No.)
E91866Mu), carry out to specifications.Wherein IL-2, IFN-γ is the TH1 cellular inflammation factors, and TGF-β can effectively facilitate T
Cell breaks up to Treg and induces Treg to express Foxp3 and IL-10.Detection finds that MSC-TNF α-AB inhibit IL- in serum
2, IL-4 expression, promotes IL-10, the expression (Figure 12) of IFN-γ and TGF-β 1.
In mRNA level in-site, MSC-TNF α-AB groups inhibit IL-2, IL-4 expression, promote IL-10, Foxp3 and
The expression (Figure 13) of TGF-β 1.Specifically, (A) is IL-2 relative mRNA level in-site in Figure 13, (B) is the relative of IL-4 in Figure 13
(C) is IL-10 relative mRNA level in-site in mRNA level in-site, Figure 13, and (D) is Foxp3 relative mRNA level in-site, Tu13Zhong in Figure 13
(E) be IFN-γ relative mRNA level in-site, in Figure 13 (A) be in IL-2 relative mRNA level in-site, Figure 13 (A) for TGF-β 1 phase
To mRNA level in-site.
Result above shows that MSC-TNF α-AB treat the expression and release for inhibiting proinflammatory inflammation factor, promotes suppression inflammation
The expression and release of the factor.
As a kind of novel stem cells treatment method, the novel cell lines MSC-TNF α-AB that the present invention is built can substantially subtract
Slow inflammatory reaction and suppression the inflammation factor, is that the inflammatory infiltration reaction of osteoarthritis serves effective mitigation.
Reagent needed for above-mentioned experiment is shown in Table 1.
The slow virus packaging plasmid of table 1 and shuttle plasmid information
293FT and mouse bone marrow cells MSC medium components are shown in Table 2 in above-mentioned experiment.
The slow virus of table 2 prepares and the required reagent information of MSC infection
293FT and mouse bone marrow cells MSC medium components are shown in Table 3 in above-mentioned experiment.
The 293FT cells of table 3 and mouse bone marrow cells MSC culture medium prescriptions
Compared with prior art, a kind of promoter provided by the present invention, the sequence such as SEQ ID NO of the promoter:2
It is shown.The promoter positive activation can express TNF Alpha antibodies genes in the presence of inflammatory factor TNF α, utilize this
Promoter can be obtained for treating osteoarthritis and the good restructuring interstital stem cell of therapeutic effect.
The present invention also provides a kind of preparation method for recombinating interstital stem cell, including:There is provided TNF Alpha antibodies gene and above-mentioned
Promoter, structure obtain slow virus expression plasmid;Wherein, the sequence of the TNF Alpha antibodies gene such as SEQ ID NO:1 institute
Show;The slow virus expression plasmid is subjected to slow virus packaging, virus liquid is obtained;Mesenchyma is infected in the virus liquid dry thin
Born of the same parents, obtain required restructuring interstital stem cell.Restructuring interstital stem cell is prepared using above-mentioned promoter, the restructuring interstitial is done
Cell can be activated under inflammatory environment by inflammatory factor TNF α, can be stably coupled to inflammation sites, be done so as to strengthen mesenchyma
The anti-inflammatory and immunoregulation capability of cell, thus can be used to treat osteoarthritis and therapeutic effect is good.
It is further that the structure of the slow virus expression plasmid includes:Step S11:By the TNF Alpha antibodies gene and
The promoter is cloned into shuttle plasmid pGFP, obtains shuttle plasmid TNF α-GFP;Step S12:With the shuttle plasmid TNF
α-GFP add the TNF Alpha antibodies gene and obtain TNF α-AB plasmid vectors as carrier;Step S13:Convert the TNF
α-AB plasmid vectors simultaneously carry out plasmid extraction and obtain the slow virus expression plasmid.By by TNF Alpha antibodies gene and promoter
Clone into shuttle plasmid pGFP, and using the shuttle plasmid TNF α-GFP of acquisition as carrier, add TNF Alpha antibodies genes, so that
TNF α-AB the plasmid vectors containing TNF Alpha antibodies gene and promoter stablized;And the promoter can be allowed to work
And expression TNF Alpha antibodies genes.
It is further that the TNF Alpha antibodies gene in the step S12 is by using in endonuclease Xho1 and nucleic acid
Enzyme cutting Xba1 carries out double digestion to the shuttle plasmid TNF α-GFP and obtained.Obtained using the shuttle plasmid TNF α-GFP
TNF Alpha antibodies genes, it is ensured that the uniformity of TNF Alpha antibodies genes used in whole preparation process, so as to ensure final institute
The stability of the restructuring interstital stem cell obtained.And according to shuttle plasmid TNF α-GFP gene order, restriction endonuclease is entered
Row selection, i.e., carry out double digestion from endonuclease Xho1 and endonuclease Xba1, so as to ensure to obtain complete and stably
TNF Alpha antibodies genes.
It is further that the time of the double digestion is 3-24h.It so can guarantee that the effect of digestion, i.e. digestion are complete.
It is further that the step S12 is to be connected using TNF Alpha antibodies gene and shuttle plasmid TNF α-GFP
It is reversed to answer, obtain TNF α-AB plasmid vectors;Shuttle plasmid TNF α's-GFP described in the reaction system of the coupled reaction is dense
Spend for 2-3ng/ μ L, the TNF Alpha antibodies gene molal quantity is 2-4 times of the shuttle plasmid TNF α-GFP molal quantitys.Pass through
Determine between shuttle plasmid TNF α-GFP concentration and TNF Alpha antibodies gene and shuttle plasmid TNF α-GFP molal quantity
Amount ratio, the coupled reaction is relatively stable, and can effectively reduce the impurity in reaction product.
Being further that the step S12 is additionally included in reaction system adds DNA ligase and connection buffer solution;Institute
The percent by volume for stating DNA ligase in reaction system is 2-3%, and the percent by volume of connection buffer solution is 8-12%.Pass through
Determine DNA ligase and connect the percent by volume of buffer solution, it is ensured that the rapidity and stability of reaction.
It is further to convert the TNF α-AB plasmid vectors to be:TNF α-AB the plasmid vectors are added into large intestine
In bacillus DH5 α competent cells, mixed solution is obtained after being well mixed;By mixed solution ice bath 20-50min, through 40-45
DEG C heat shock effect 30-90s under zero degree environment after cooling down 1-4min;Then mixed solution is placed in culture medium and cultivated, obtained
To the nutrient solution containing the slow virus expression plasmid.First, by selecting bacillus coli DH 5 alpha competent cell, both it can guarantee that
The expression of TNF α-AB plasmid vectors, and the conversion of TNF α-AB plasmid vectors will not be adversely affected.Secondly, pass through
By heat shock after mixed solution ice bath 20-50min, the operation of 1-4min on ice is and then placed in, it is ensured that transformation efficiency.
The present invention also provides a kind of restructuring interstital stem cell, is integrated with promoter and TNF Alpha antibodies genes;The promoter
Sequence such as SEQ ID NO:Shown in 2, the sequence such as SEQ ID NO of the TNF Alpha antibodies gene:Shown in 1.The restructuring interstitial is done
Promoter and TNF Alpha antibodies genes are integrated with cell, can be activated under inflammatory environment by inflammatory factor TNF α, can be stably
Inflammation sites are attached to, so as to strengthen the anti-inflammatory and immunoregulation capability of mescenchymal stem cell, thus can be used to treat Bones and joints
It is scorching and therapeutic effect is good.
The present invention also provides a kind of application for recombinating interstital stem cell, and above-mentioned restructuring interstital stem cell is used to prepare and treated
The medicine of osteoarthritis.The effect of resulting drug therapy osteoarthritis is good.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all originals in the present invention
Any modification made within then, equivalent substitution and improvement etc. all should be comprising within protection scope of the present invention.
Sequence table
<110>Zhong Jihengrun International Holdings Ltds
<120>Promoter, restructuring interstital stem cell and its preparation method and application
<150>HK16105540.6
<151>2016-05-16
<160>6
<210>1
<211>465
<212>DNA
<213>Artificial sequence
<400>1
atgctacgctcttcgtcccagaactcatcggataagcctgtcgcgcacgtggtagccaat 60
caccaagtggaagagcagctagagtggctctcgcaacgcgccaatgcgctactggctaac 120
ggtatggacctgaaggacaatcaactggtagttccggcagacggtctatacctggtatac 180
tccaggtgcttttcaagggacaaggttgccctgactatgtgctgctaacgcacactgttt 240
cacggttcgctatttcgtaccaggaaaaggttaacctgctatccgcggttaaatccccgt 300
gcccaaaggacactcccgaaggggcggaacttaagccttggtacgaacctatttacctgg 360
gtggagttttccaacttgaaaaaggcgaccagctttcagccgaagtaaatcttcccaagt 420
catcaagtgtatcatatgccaagtacgccccctattgacgtcaatg 465
<210>2
<211>707
<212>DNA
<213>Artificial sequence
<220>
<223>Promoter
<400>2
tgggatctga gcttcttcgt gaaacacggg gcagaggagg caccagaact ctcctctgac 60
caactgcccc acagcacaca tatcctcaaa ggatagtctt gaatacgtga tggaagaatt 120
aaagagagtg aggtctgaag aaaatcagcc ctctcggggt ttcctttggg taactgagtg 180
ctaaggtgac ttccgagtca gcaagaaata tcggacgttc aacccaggtt gagtggagga 240
aacaattatt tctcaatcct aatatgttct ggaatagccc atttatccac gtcattatga 300
cctgggagtg cgtgaatgga atccacagat gagggcctct gtacatagaa cagctgtctg 360
cctcaggaaa tacaactttt agtattgaga agctaaaaag aaaaaaaaat taaaagagag 420
gtagcccata ctaaaaatag ctgtaatgca gaagttcatt ccgaccagtt ctttagcgct 480
tacaatgcaa aaaaaaggga aaggaaaaaa aaaaagaaag aaattaaact caaaaattgc 540
atggtttaga agagggagga ggagcctgaa taacaaaaac ctttgccagg aaggccccac 600
tgagccttca gtataaaagg gggaccaaga acaggaggtc tacatttaga gacttgctct 660
tgcactacca aagccacaag gcagccttgc agaaaagaga gctccat 707
<210>3
<211>18
<212>DNA
<213>Artificial sequence
<400>3
gctagagtggctctcgca 18
<210>4
<211>18
<212>DNA
<213>Artificial sequence
<400>4
cgaaggggcggaacttaa
18
<210>5
<211>20
<212> DNA
<213>Artificial sequence
<400>5
agagggaaatcgtgcgtgac 20
<210>6
<211>20
<212>DNA
<213>Artificial sequence
<400>6
tgctggaaggtggacagtgag 20
Claims (10)
1. a kind of promoter, it is characterised in that:The sequence of the promoter such as SEQ ID NO:Shown in 2.
2. a kind of preparation method for recombinating interstital stem cell, it is characterised in that:Including:TNF Alpha antibodies gene is provided and right will
The promoter described in 1 is sought, structure obtains slow virus expression plasmid;Wherein, the sequence of the TNF Alpha antibodies gene such as SEQ ID
NO:Shown in 1;
The slow virus expression plasmid is subjected to slow virus packaging, virus liquid is obtained;
Mescenchymal stem cell is infected in the virus liquid, required restructuring interstital stem cell is obtained.
3. the preparation method of interstital stem cell is recombinated as stated in claim 2, it is characterised in that:The slow virus expression plasmid
Structure include:
Step S11:The TNF Alpha antibodies gene and the promoter are cloned into shuttle plasmid pGFP, shuttle plasmid TNF is obtained
α-GFP;
Step S12:Using the shuttle plasmid TNF α-GFP as carrier, add the TNF Alpha antibodies gene and obtain TNF α-AB
Plasmid vector;
Step S13:Convert the TNF α-AB plasmid vectors and carry out plasmid extraction and obtain the slow virus expression plasmid.
4. the preparation method of interstital stem cell is recombinated as claimed in claim 3, it is characterised in that:The TNF Alpha antibodies gene
Double digestion is carried out by using endonuclease Xho1 and endonuclease Xba1 to the shuttle plasmid TNF α-GFP to obtain.
5. the preparation method of interstital stem cell is recombinated as claimed in claim 4, it is characterised in that:The time of the double digestion is
3-24h。
6. the preparation method of interstital stem cell is recombinated as claimed in claim 3, it is characterised in that:The step S12 is utilization
TNF Alpha antibodies gene and shuttle plasmid TNF α-GFP are attached reaction, obtain TNF α-AB plasmid vectors;The connection
The concentration of shuttle plasmid TNF α-GFP described in the reaction system of reaction is 2-3ng/ μ L, the TNF Alpha antibodies gene molal quantity
For 2-4 times of the shuttle plasmid TNF α-GFP molal quantitys.
7. the preparation method of interstital stem cell is recombinated as recited in claim 6, it is characterised in that:The step S12 also includes
DNA ligase and connection buffer solution are added in reaction system;The percent by volume of DNA ligase is 2- in the reaction system
3%, the percent by volume of connection buffer solution is 8-12%.
8. the preparation method of interstital stem cell is recombinated as claimed in claim 3, it is characterised in that:Convert the TNF α-AB matter
Grain carrier specifically includes following steps:TNF α-AB the plasmid vectors are added in bacillus coli DH 5 alpha competent cell, mixed
Mixed solution is obtained after closing uniformly;By mixed solution ice bath 20-50min, ice again after acting on 30-90s through 40-45 DEG C of heat shock
Bathe 1-4min;Then mixed solution is placed in culture medium and cultivated, obtain the nutrient solution containing the slow virus expression plasmid.
9. one kind restructuring interstital stem cell, it is characterised in that:It is integrated with promoter and TNF Alpha antibodies genes;The promoter
Sequence such as SEQ ID NO:Shown in 2, the sequence such as SEQ ID NO of the TNF Alpha antibodies gene:Shown in 1.
10. a kind of application for recombinating interstital stem cell, it is characterised in that:By the restructuring interstital stem cell described in claim 9
Medicine for preparing treatment osteoarthritis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HK16105540.6 | 2016-05-16 | ||
HK16105540.6A HK1217268A2 (en) | 2016-05-16 | 2016-05-16 | Method of msc-tnf-ab engineered stem cells and application of the product hereof msc-tnf-ab |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107034217A true CN107034217A (en) | 2017-08-11 |
Family
ID=57610765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611200969.9A Withdrawn CN107034217A (en) | 2016-05-16 | 2016-12-22 | Promoter, recombinant mesenchymal stem cell, and preparation method and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN107034217A (en) |
HK (1) | HK1217268A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110951693A (en) * | 2019-12-05 | 2020-04-03 | 北京兴元和济生命医学科技有限公司 | Method for knocking in exogenous gene into mesenchymal stem cells at fixed point by using CRISPR-Cas9 system |
CN114934070A (en) * | 2022-01-18 | 2022-08-23 | 生物岛实验室 | Mesenchymal stem cells and anti-inflammatory application thereof |
-
2016
- 2016-05-16 HK HK16105540.6A patent/HK1217268A2/en not_active IP Right Cessation
- 2016-12-22 CN CN201611200969.9A patent/CN107034217A/en not_active Withdrawn
Non-Patent Citations (3)
Title |
---|
N. SAIDENBERG-KERMANAC’H 等: "TNF-a antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis", 《BONE》 * |
O REILLY,A.S. 等: "GenBank 登录号:HQ014592.1", 《NCBI》 * |
马贵亮 等: "重组TNF-α慢病毒感染的脐血间质干细胞对胃癌移植瘤生长的抑制作用", 《中国肿瘤生物治疗杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110951693A (en) * | 2019-12-05 | 2020-04-03 | 北京兴元和济生命医学科技有限公司 | Method for knocking in exogenous gene into mesenchymal stem cells at fixed point by using CRISPR-Cas9 system |
CN114934070A (en) * | 2022-01-18 | 2022-08-23 | 生物岛实验室 | Mesenchymal stem cells and anti-inflammatory application thereof |
Also Published As
Publication number | Publication date |
---|---|
HK1217268A2 (en) | 2016-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6633056B2 (en) | Exosome treatment of graft-versus-host disease (GVHD) or epidermolysis bullosa (EB) | |
CN103570818B (en) | Tumor antigenic polypeptide and the purposes as tumor vaccine thereof | |
CN106591306B (en) | Application of the siRNA of targeting interference tumour PTN-PTPRZ1 access in immunotherapy of tumors | |
CN106167791A (en) | MSC TNF α AB stem cell and its preparation method and application | |
CN105296431A (en) | Tumor binding specific gamma delta TCR gene modified alpha beta T cell and cancer suppression application thereof | |
CN107164332A (en) | Leukaemia's excretion body that the TGF β 1 modified through interference sequence keep silent and its preparation method and application | |
CN107557337A (en) | A kind of immunocyte of safety-type Chimeric antigen receptor modifications of anti-ROR1 and its application | |
CN103966167B (en) | Cell culture compositions and purposes for original cuiture tumour cell | |
CN104928254A (en) | Mesenchymal stem cell for repairing radioactive intestinal epithelial injury by directionally transporting Rspol | |
Soleto et al. | Regulation of IgM+ B cell activities by rainbow trout APRIL reveals specific effects of this cytokine in lower vertebrates | |
EA012520B1 (en) | Process for producing cytotoxic lymphocytes | |
CN107034217A (en) | Promoter, recombinant mesenchymal stem cell, and preparation method and application thereof | |
CN101058809B (en) | Use of humanization modified rat ING4 gene and adenovirus expression vectors in preparing medicine for treating lung cancer | |
WO2004055053A1 (en) | Tumor vaccine | |
CN103948944A (en) | Broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine | |
CN110194800B (en) | Fusion protein, extracellular exosome and tumor vaccine and application thereof | |
CN114703142A (en) | Human induced pluripotent stem cell, construction method and application thereof | |
CN106267416B (en) | AIDS therapeutic equipment | |
CN106065401B (en) | Treatment use of the lentivirus mediated CXCR7 high expression engineering endothelial progenitor cells in ischemic disease | |
CN107987147A (en) | A kind of MG53 polymers preparation method and its usage | |
Currie | Promotion of fibrosarcoma cell growth by products of syngeneic host macrophages | |
CN103421729B (en) | Gene recombined swine cholera salmonella choleraesuis vaccine for blue-ear disease and application thereof | |
CN106267414B (en) | AIDS immunologic purging device | |
CN105012951A (en) | Method of linked adhesion molecule JAM-A in promotion of skin wound restoration, and application of linked adhesion molecule JAM-A | |
CN114908054B (en) | Cell membrane vesicle and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170811 |